Integra Lifesciences Analyst Scoreboard
Analysts have shared a range of opinions on Integra Lifesciences (NASDAQ: IART) in the past quarter, showcasing a mix of bullish and bearish sentiments. Here’s a breakdown of recent ratings and insights:
Total Ratings:
– Bullish: 0
– Somewhat Bullish: 3
– Indifferent: 2
– Somewhat Bearish: 0
– Bearish: 0
Recent Trends:
– Somewhat Bullish in the Last 30 Days: 1
12-Month Price Targets:
– Average Target: $48.6
– High Estimate: $55.00
– Low Estimate: $44.00
– Current Average Target Increase: 9.21% from the previous average of $44.50
Analyst Actions and Insights:
Analysts have made significant adjustments to their ratings and price targets for Integra Lifesciences in response to market dynamics and company performance:
– David Turkaly (JMP Securities): Lowered Market Outperform rating to $49.00 from $55.00
– Richard Newitter (Truist Securities): Raised Hold rating to $46.00 from $44.00
– Larry Biegelsen (Wells Fargo): Raised Overweight rating to $49.00 from $40.00
Key Financial Indicators:
– Return on Equity (ROE): Strong financial management with an ROE of 1.2%
– Return on Assets (ROA): Exceptional financial health with an ROA exceeding industry averages at 0.52%
– Debt Management: Challenges with a high debt-to-equity ratio of 1.07, indicating potential financial strain
Analyst ratings and price targets offer valuable insights into market expectations for Integra Lifesciences, assisting investors in making informed decisions based on expert evaluations.
Integra LifeSciences Holdings Corporation (IART) Stock Performance Declines on February 29, 2024: Analysis and Recommendations
On February 29, 2024, Integra LifeSciences Holdings Corporation (IART) experienced a decline in its stock performance. The price of IART shares decreased by $1.76 since the market last closed, representing a 4.55% drop. The stock closed at $36.91. In after-hours trading, the stock dropped an additional $0.27. The drop in price on February 29th may have been influenced by a variety of factors, such as market conditions, company performance, or external events. Investors may have reacted to news or developments that negatively impacted their perception of the company’s future prospects. For investors considering IART stock, it is important to conduct thorough research and analysis before making any decisions. It is also advisable to consult with a financial advisor to assess the potential risks and rewards of investing in a stock that is trading near its 52-week low. Overall, the performance of IART stock on February 29, 2024, reflects the challenges and uncertainties that investors may face in the stock market. It serves as a reminder of the importance of staying informed and vigilant in monitoring investments to make informed decisions.
Integra LifeSciences Holdings Corporation (IART) Financial Results Analysis: Revenue Increases, Net Income Declines
On February 29, 2024, investors in Integra LifeSciences Holdings Corporation (IART) were closely monitoring the company’s stock performance following the release of its financial results. According to data from CNN Money, IART reported total revenue of $1.54 billion for the past year, which remained flat compared to the previous year. However, there was a 3.82% increase in total revenue since the last quarter, reaching $397.04 million.
Despite the increase in quarterly revenue, IART’s net income saw a significant decline. The company reported a net income of $67.74 million for the past year, marking a 62.48% decrease from the previous year. Net income for the last quarter was $19.83 million, which remained flat compared to the previous quarter.
Earnings per share (EPS) also saw a decline for IART. The company reported an EPS of $0.84 for the past year, representing a 61.0% decrease from the previous year. EPS for the last quarter was $0.25, which remained flat compared to the previous quarter.
Overall, the financial results for IART on February 29, 2024, showed mixed performance. While total revenue saw a slight increase from the previous quarter, net income and EPS experienced declines. Investors will be closely monitoring future developments and company announcements to assess the company’s growth prospects and stock performance.
